|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquired
|
gptkb:Gilead_Sciences
|
|
gptkbp:acquisition
|
gptkb:2017
|
|
gptkbp:advocates_for
|
supportive
|
|
gptkbp:business_model
|
gptkb:Company
|
|
gptkbp:ceo
|
gptkb:Christi_Shaw
|
|
gptkbp:clinical_trial
|
gptkb:significant
various
high
ongoing
positive
extensive
recognized
published
leading edge
CART-cell therapy trials
KTE-AL trials
KTE-BCM trials
KTE-C19 trials
KTE-CL trials
KTE-CR trials
KTE-EBV trials
KTE-GL trials
KTE-IL trials
KTE-ML trials
KTE-OL trials
KTE-PL trials
KTE-TP trials
KTE-X19 trials
Yescarta trials
|
|
gptkbp:collaborations
|
ongoing
academic institutions
established
|
|
gptkbp:committee
|
established
|
|
gptkbp:community_engagement
|
active
|
|
gptkbp:employees
|
over 500
|
|
gptkbp:focus
|
gptkb:drug
|
|
gptkbp:founded
|
gptkb:2009
|
|
gptkbp:founder
|
gptkb:Arie_Belldegrun
|
|
gptkbp:global_presence
|
expanding
|
|
gptkbp:headquarters
|
gptkb:Santa_Monica,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Kite Pharma
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:innovation
|
leading
contributing
|
|
gptkbp:investment
|
gptkb:significant
gptkb:Gilead_Sciences
venture capital firms
|
|
gptkbp:key_people
|
gptkb:David_M._H._Lee
gptkb:Robert_A._Nussbaum
gptkb:David_Chang
gptkb:Michael_A._H._Lee
gptkb:Kathy_H._H._Lee
gptkb:John_R._Mc_Kinley
gptkb:Arie_Belldegrun
gptkb:Christi_Shaw
|
|
gptkbp:language_of_instruction
|
diverse
|
|
gptkbp:leadership
|
gptkb:Arie_Belldegrun
|
|
gptkbp:license
|
submitted
|
|
gptkbp:location
|
gptkb:United_States
|
|
gptkbp:market
|
global
|
|
gptkbp:marketing_strategy
|
innovative
|
|
gptkbp:mission
|
transform cancer treatment
|
|
gptkbp:notable_products
|
gptkb:Yescarta
gptkb:Kymriah
|
|
gptkbp:partnership
|
gptkb:healthcare_organization
|
|
gptkbp:partnerships
|
various pharmaceutical companies
strategic
biopharmaceutical companies
focused
|
|
gptkbp:platform
|
proprietary
|
|
gptkbp:population
|
cancer patients
|
|
gptkbp:products
|
advanced
therapeutic drugs
|
|
gptkbp:publishes
|
numerous
|
|
gptkbp:receives_funding_from
|
substantial
|
|
gptkbp:regulatory_compliance
|
gptkb:FDA
frequent
|
|
gptkbp:research
|
ongoing
|
|
gptkbp:research_areas
|
gptkb:vaccine
oncology
|
|
gptkbp:research_focus
|
gptkb:drug
personalized medicine
hematologic malignancies
|
|
gptkbp:revenue
|
increased annually
$1 billion (2020)
|
|
gptkbp:side_effect
|
transformative
|
|
gptkbp:specializes_in
|
gptkb:drug
|
|
gptkbp:sustainability_initiatives
|
diverse
|
|
gptkbp:symbol
|
KITE
|
|
gptkbp:technology
|
genetic engineering
achieved
|
|
gptkbp:treatment
|
gptkb:drug
improving
promising
effective
|
|
gptkbp:type_of_care
|
prioritized
|
|
gptkbp:vision
|
cellular therapy
|
|
gptkbp:website
|
www.kitepharma.com
|
|
gptkbp:bfsParent
|
gptkb:Celgene_Corporation
gptkb:Takeda_Pharmaceutical_Company
|
|
gptkbp:bfsLayer
|
3
|